TargED Biopharmaceuticals

Executive Summary

TargED Biopharmaceuticals is a Netherlands-based biotechnology company pioneering targeted thrombolysis using its proprietary platform that combines small VHH antibodies with therapeutic enzymes. Founded in 2018, the company aims to improve the treatment of thrombosis by delivering potent enzymes directly to clot sites, potentially reducing bleeding risks associated with current therapies. TargED's lead candidate is in Phase 1 clinical development, representing a novel approach in the thrombosis space. The company's targeted enzyme delivery platform offers a first-in-class mechanism that could address significant unmet needs in both arterial and venous thrombosis. As a private entity, TargED has not disclosed total funding or valuation, but its innovative technology positions it as a potential acquisition target or partnership candidate for larger cardiovascular players.

Upcoming Catalysts (preview)

• H2 2026Phase 1 clinical data readout60% success
• TBDPotential partnership or licensing deal for thrombosis program40% success
• 2026Orphan Drug Designation or other regulatory milestone30% success